Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

RCP is a human breast cancer-promoting gene with Ras-activating function.

Zhang J, Liu X, Datta A, Govindarajan K, Tam WL, Han J, George J, Wong C, Ramnarayanan K, Phua TY, Leong WY, Chan YS, Palanisamy N, Liu ET, Karuturi KM, Lim B, Miller LD.

J Clin Invest. 2009 Aug;119(8):2171-83. doi: 10.1172/JCI37622. Epub 2009 Jul 20.

2.

Genomic amplicons target vesicle recycling in breast cancer.

Mills GB, Jurisica I, Yarden Y, Norman JC.

J Clin Invest. 2009 Aug;119(8):2123-7. doi: 10.1172/JCI40256. Epub 2009 Jul 20.

3.

Transforming function of the LSM1 oncogene in human breast cancers with the 8p11-12 amplicon.

Streicher KL, Yang ZQ, Draghici S, Ethier SP.

Oncogene. 2007 Mar 29;26(14):2104-14. Epub 2006 Sep 25.

4.

RCP induces Slug expression and cancer cell invasion by stabilizing ╬▓1 integrin.

Hwang MH, Cho KH, Jeong KJ, Park YY, Kim JM, Yu SL, Park CG, Mills GB, Lee HY.

Oncogene. 2017 Feb 23;36(8):1102-1111. doi: 10.1038/onc.2016.277. Epub 2016 Aug 15.

PMID:
27524413
5.

Is Rab25 a tumor promoter or suppressor--context dependency on RCP status?

Tang BL.

Tumour Biol. 2010 Aug;31(4):359-61. doi: 10.1007/s13277-010-0030-z. Epub 2010 Apr 8.

PMID:
20376596
6.

Crk adaptor proteins act as key signaling integrators for breast tumorigenesis.

Fathers KE, Bell ES, Rajadurai CV, Cory S, Zhao H, Mourskaia A, Zuo D, Madore J, Monast A, Mes-Masson AM, Grosset AA, Gaboury L, Hallet M, Siegel P, Park M.

Breast Cancer Res. 2012 May 8;14(3):R74.

7.

Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer.

Yang ZQ, Streicher KL, Ray ME, Abrams J, Ethier SP.

Cancer Res. 2006 Dec 15;66(24):11632-43.

8.

A novel role for flotillin-1 in H-Ras-regulated breast cancer aggressiveness.

Koh M, Yong HY, Kim ES, Son H, Jeon YR, Hwang JS, Kim MO, Cha Y, Choi WS, Noh DY, Lee KM, Kim KB, Lee JS, Kim HJ, Kim H, Kim HH, Kim EJ, Park SY, Kim HS, Moon WK, Choi Kim HR, Moon A.

Int J Cancer. 2016 Mar 1;138(5):1232-45. doi: 10.1002/ijc.29869. Epub 2015 Oct 9.

9.

A role for the scaffolding adapter GAB2 in breast cancer.

Bentires-Alj M, Gil SG, Chan R, Wang ZC, Wang Y, Imanaka N, Harris LN, Richardson A, Neel BG, Gu H.

Nat Med. 2006 Jan;12(1):114-21. Epub 2005 Dec 20.

PMID:
16369543
10.

Bmi-1 cooperates with H-Ras to transform human mammary epithelial cells via dysregulation of multiple growth-regulatory pathways.

Datta S, Hoenerhoff MJ, Bommi P, Sainger R, Guo WJ, Dimri M, Band H, Band V, Green JE, Dimri GP.

Cancer Res. 2007 Nov 1;67(21):10286-95.

11.

Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor-alpha genes on in vitro transformation of human mammary epithelial cells.

Ciardiello F, Gottardis M, Basolo F, Pepe S, Normanno N, Dickson RB, Bianco AR, Salomon DS.

Mol Carcinog. 1992;6(1):43-52.

PMID:
1354442
12.

HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition.

Wu X, Chen H, Parker B, Rubin E, Zhu T, Lee JS, Argani P, Sukumar S.

Cancer Res. 2006 Oct 1;66(19):9527-34. Erratum in: Cancer Res. 2015 Jun 1;75(11):2401.

13.

Global gene expression profiling unveils S100A8/A9 as candidate markers in H-ras-mediated human breast epithelial cell invasion.

Moon A, Yong HY, Song JI, Cukovic D, Salagrama S, Kaplan D, Putt D, Kim H, Dombkowski A, Kim HR.

Mol Cancer Res. 2008 Oct;6(10):1544-53. doi: 10.1158/1541-7786.MCR-08-0189.

14.

Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis.

Kang W, Tong JH, Chan AW, Lee TL, Lung RW, Leung PP, So KK, Wu K, Fan D, Yu J, Sung JJ, To KF.

Clin Cancer Res. 2011 Apr 15;17(8):2130-9. doi: 10.1158/1078-0432.CCR-10-2467. Epub 2011 Feb 23.

15.

Angiomotin promotes breast cancer cell proliferation and invasion.

Lv M, Lv M, Chen L, Qin T, Zhang X, Liu P, Yang J.

Oncol Rep. 2015 Apr;33(4):1938-46. doi: 10.3892/or.2015.3780. Epub 2015 Feb 3.

PMID:
25647626
16.

Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways.

Iwanaga R, Wang CA, Micalizzi DS, Harrell JC, Jedlicka P, Sartorius CA, Kabos P, Farabaugh SM, Bradford AP, Ford HL.

Breast Cancer Res. 2012 Jul 5;14(4):R100. doi: 10.1186/bcr3219.

17.
18.

VRK2 inhibits mitogen-activated protein kinase signaling and inversely correlates with ErbB2 in human breast cancer.

Fernández IF, Blanco S, Lozano J, Lazo PA.

Mol Cell Biol. 2010 Oct;30(19):4687-97. doi: 10.1128/MCB.01581-09. Epub 2010 Aug 2.

19.

TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation.

Oberst MD, Beberman SJ, Zhao L, Yin JJ, Ward Y, Kelly K.

BMC Cancer. 2008 Jul 2;8:189. doi: 10.1186/1471-2407-8-189.

20.

KAT6A, a chromatin modifier from the 8p11-p12 amplicon is a candidate oncogene in luminal breast cancer.

Turner-Ivey B, Guest ST, Irish JC, Kappler CS, Garrett-Mayer E, Wilson RC, Ethier SP.

Neoplasia. 2014 Aug;16(8):644-55. doi: 10.1016/j.neo.2014.07.007.

Supplemental Content

Support Center